- Home
- MGNX vs GRWG Comparison
MGNX vs GRWG Comparison
Compare MGNX & GRWG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- GRWG
- Stock Information
- Founded
- MGNX 2000
- GRWG 2008
- Country
- MGNX United States
- GRWG United States
- Employees
- MGNX N/A
- GRWG N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- GRWG RETAIL: Building Materials
- Sector
- MGNX Health Care
- GRWG Consumer Discretionary
- Exchange
- MGNX Nasdaq
- GRWG Nasdaq
- Market Cap
- MGNX 99.7M
- GRWG 98.0M
- IPO Year
- MGNX 2013
- GRWG N/A
- Fundamental
- Price
- MGNX $1.82
- GRWG $1.78
- Analyst Decision
- MGNX Hold
- GRWG Strong Buy
- Analyst Count
- MGNX 6
- GRWG 1
- Target Price
- MGNX $3.20
- GRWG $2.50
- AVG Volume (30 Days)
- MGNX 630.9K
- GRWG 712.2K
- Earning Date
- MGNX 11-04-2025
- GRWG 11-11-2025
- Dividend Yield
- MGNX N/A
- GRWG N/A
- EPS Growth
- MGNX N/A
- GRWG N/A
- EPS
- MGNX N/A
- GRWG N/A
- Revenue
- MGNX $165,495,000.00
- GRWG $164,108,000.00
- Revenue This Year
- MGNX N/A
- GRWG N/A
- Revenue Next Year
- MGNX N/A
- GRWG N/A
- P/E Ratio
- MGNX N/A
- GRWG N/A
- Revenue Growth
- MGNX 303.47
- GRWG N/A
- 52 Week Low
- MGNX $0.99
- GRWG $0.82
- 52 Week High
- MGNX $5.10
- GRWG $2.25
- Technical
- Relative Strength Index (RSI)
- MGNX 51.87
- GRWG 54.16
- Support Level
- MGNX $1.69
- GRWG $1.74
- Resistance Level
- MGNX $1.83
- GRWG $1.86
- Average True Range (ATR)
- MGNX 0.10
- GRWG 0.13
- MACD
- MGNX 0.00
- GRWG -0.02
- Stochastic Oscillator
- MGNX 56.00
- GRWG 34.91
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About GRWG GrowGeneration Corp.
GrowGeneration Corp owns and operates specialty retail hydroponic and organic gardening stores. The firm is a marketer and distributor of nutrients, growing media, indoor and greenhouse lighting, ventilation systems and accessories for hydroponic gardening. The Company has two reportable segments, including Cultivation and Gardening segment, composed of the Company's hydroponic and organic gardening business; and the Storage Solutions segment, composed of the Company's benching, racking, and storage solutions business.